摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-chloro-4-(2-pyridylmethoxy)anilino)-5-fluoroquinazoline | 524955-33-7

中文名称
——
中文别名
——
英文名称
4-(3-chloro-4-(2-pyridylmethoxy)anilino)-5-fluoroquinazoline
英文别名
N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-fluoroquinazolin-4-amine
4-(3-chloro-4-(2-pyridylmethoxy)anilino)-5-fluoroquinazoline化学式
CAS
524955-33-7
化学式
C20H14ClFN4O
mdl
——
分子量
380.809
InChiKey
JSULJVFIMLRJST-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    539.9±50.0 °C(Predicted)
  • 密度:
    1.409±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    27
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    59.9
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(3-chloro-4-(2-pyridylmethoxy)anilino)-5-fluoroquinazolineN-乙酰乙醇胺 、 sodium hydride 作用下, 以 2,4-滴二甲胺盐 为溶剂, 反应 18.5h, 以78%的产率得到4-(3-chloro-4-(2-pyridylmethoxy)anilino)-5-hydroxyquinazoline
    参考文献:
    名称:
    [EN] QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES
    [FR] DERIVES DE QUINAZOLINE UTILISES COMME TYROSINE KINASES DU RECEPTEUR ERBB
    摘要:
    该发明涉及公式(I)的喹唑啉衍生物,其中R1、R2、R3、R4、R5、R6、R7、X1、Q1、m和n中的每个都具有描述中定义的任意含义;它们的制备方法,含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途,用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤。
    公开号:
    WO2005118572A1
  • 作为产物:
    参考文献:
    名称:
    5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase
    摘要:
    Starting from a 6,7-substituted quinazoline lead 4, optimisation of 5-substituted quinazolines containing an extended aniline motif led to potent and selective inhibitors of erbB2 receptor tyrosine kinase, and a representative compound 12a inhibited tumour growth in a mouse xenograft model. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.06.068
点击查看最新优质反应信息

文献信息

  • [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
    申请人:ASTRAZENECA AB
    公开号:WO2005051923A1
    公开(公告)日:2005-06-09
    A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Formula (I)的喹唑啉衍生物:其中取代基如文本中定义的那样,用于生产抗增殖效应,该效应通过在诸如人类等恒温动物中抑制erbB2受体酪氨酸激酶而产生。
  • [EN] 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS<br/>[FR] DERIVES DE 4-ANILINO-QUINAZOLINE UTILISES COMME AGENTS ANTIPROLIFERATIFS
    申请人:ASTRAZENECA AB
    公开号:WO2004093880A1
    公开(公告)日:2004-11-04
    A quinazoline derivative of the formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    一种式(I)的喹唑啉衍生物,其中取代基如文本中所定义,用于在温血动物(如人)中产生抗增殖效应,该效应通过部分或完全抑制erbB2受体酪氨酸激酶而产生。
  • A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
    作者:Bernard Barlaam、Peter Ballard、Robert H. Bradbury、Richard Ducray、Hervé Germain、D. Mark Hickinson、Kevin Hudson、Jason G. Kettle、Teresa Klinowska、Françoise Magnien、Donald J. Ogilvie、Annie Olivier、Stuart E. Pearson、James S. Scott、Abid Suleman、Cath B. Trigwell、Michel Vautier、Robin D. Whittaker、Robin Wood
    DOI:10.1016/j.bmcl.2007.11.052
    日期:2008.1
    initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of erbB2 in a mouse BT474C xenograft model after oral administration.
    从包含碱性5取代基的初始铅1开始,对乙醇酰胺衍生的中性5取代基的优化导致了具有良好药代动力学的有效erbB2抑制剂。口服给药后,在小鼠BT474C异种移植模型中,代表性化合物19和21抑制erbB2的磷酸化。
  • [EN] QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME AGENTS ANTI-TUMEUR
    申请人:ASTRAZENECA AB
    公开号:WO2005026152A1
    公开(公告)日:2005-03-24
    A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    一种喹唑啉衍生物的化学式(I):(请参阅附上的纸质副本以获取化学式)化学式 I,其中取代基如文本中定义的那样,用于生产抗增殖作用,该作用通过在温血动物(如人)中部分或完全抑制erbB2受体酪氨酸激酶而产生。
  • Quinazoline derivatives as antitumor agents
    申请人:Hennequin Francois Andre Laurent
    公开号:US20050043336A1
    公开(公告)日:2005-02-24
    The invention concerns quinazoline derivatives of Formula (I); wherein each of Q 1 , Q 2 , Z, R 1 , R 2 , R 3 , and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosin kinases.
    该发明涉及公式(I)的喹唑啉衍生物;其中Q1,Q2,Z,R1,R2,R3和m的每个定义在说明中具有任何意义;它们的制备过程,包含它们的制药组合物以及它们在制造对erbB受体酪氨酸激酶抑制敏感的肿瘤的预防或治疗药物中的使用。
查看更多